1. Home
  2. CSR vs OMER Comparison

CSR vs OMER Comparison

Compare CSR & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo D/B/A Centerspace

CSR

D/B/A Centerspace

HOLD

Current Price

$64.43

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$11.63

Market Cap

894.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSR
OMER
Founded
1970
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
894.8M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
CSR
OMER
Price
$64.43
$11.63
Analyst Decision
Hold
Strong Buy
Analyst Count
6
5
Target Price
$70.20
$32.50
AVG Volume (30 Days)
137.1K
2.6M
Earning Date
02-17-2026
11-13-2025
Dividend Yield
4.79%
N/A
EPS Growth
N/A
N/A
EPS
1.82
N/A
Revenue
$273,450,000.00
N/A
Revenue This Year
$7.24
N/A
Revenue Next Year
$2.63
N/A
P/E Ratio
$35.23
N/A
Revenue Growth
5.72
N/A
52 Week Low
$52.76
$2.95
52 Week High
$69.15
$17.65

Technical Indicators

Market Signals
Indicator
CSR
OMER
Relative Strength Index (RSI) 45.04 45.94
Support Level $63.41 $11.45
Resistance Level $66.25 $12.68
Average True Range (ATR) 1.37 0.72
MACD -0.15 -0.25
Stochastic Oscillator 21.71 9.51

Price Performance

Historical Comparison
CSR
OMER

About CSR D/B/A Centerspace

Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: